MaaT Pharma announced on 4/9/19 that the independent Data and Safety Monitoring Board (DSMB) recommended the continuation, without amendment, of the ongoing Phase II HERACLES study (NCT03359980).... read more
MaaT Pharma announced on 4/9/19 that the independent Data and Safety Monitoring Board (DSMB) recommended the continuation, without amendment, of the ongoing Phase II HERACLES study (NCT03359980).... read more
On 4/8/19 researchers from Azitra, Inc., in collaboration withindependent, nonprofit biomedical research institutionThe Jackson Laboratory (JAX), announced they have demonstrated the feasibility... read more
OZ, a global consulting company enhancing customer experiences through digital innovation, recently launched a first-of-its-kind application that brings an augmented reality (AR) environment to... read more
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, Provided the results of its first human study on 4/8/19.
The study was primarily undertaken to show... read more
Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, updated its S-1 Filing. The company is proposing... read more